Antiplatelet or Anticoagulant Treatment and Outpatient Procedure, Gynaecology

exp date isn't null, but text field is


Factor Xa inhibitors Apixaban (Eliquis®), Edoxaban (Lixiana®) and Rivaroxiban (Xarelto®) are the preferred anticoagulant therapy for treatment of venous thromboembolism and non-valvular atrial fibrillation (AF). Within NHS GG&C, edoxaban is the treatment of choice for AF and Apixaban for pulmonary embolism. They are direct oral anticoagulants (DOACs) and are Factor Xa inhibitors. An additional DOAC, dabigatran (a direct thrombin inhibitor), is also in use within NHS GG&C in a small number of patients.

NOTE: this guideline is hosted on the NHSGGC Obstetrics & Gynaecology Handbook website. Clicking on the link below will open the guideline in a new window.


Use the button below to access this resource item.

Access this resource